NAV

Oxatomide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Oxatomide is an antihistamine indicated in the treatment and prevention of allergic symptoms.

Generic Name
Oxatomide
DrugBank Accession Number
DB12877
Background

Oxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne.

Type
Small Molecule
Groups
Approved, Investigational
Structure
3D
Similar Structures
Weight
Average: 426.564
Monoisotopic: 426.241961602
Chemical Formula
C27H30N4O
Synonyms
  • Oxatomida
  • Oxatomide
  • Oxatomidum
External IDs
  • KW-4354
  • McN-JR 35443
  • R 35 443
  • R 35,443
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAsthma, allergic••••••••••••
Treatment ofAtopic dermatitis (ad)••••••••••••
Treatment ofChronic urticaria••••••••••••
Symptomatic treatment ofPruritus•••••••••••••••
Treatment ofRhinitis••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
PathwayCategory
Oxatomide H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Oxatomide.
AdenosineThe risk or severity of QTc prolongation can be increased when Adenosine is combined with Oxatomide.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with Oxatomide.
AlbuterolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Oxatomide.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Oxatomide.
Food Interactions
  • Take with food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Celtect / Tinset

Categories

ATC Codes
R06AE06 — Oxatomide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Benzimidazoles / N-alkylpiperazines / Aralkylamines / N-substituted imidazoles / Heteroaromatic compounds / Ureas / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds
show 2 more
Substituents
1,4-diazinane / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzimidazole / Diphenylmethane / Heteroaromatic compound / Hydrocarbon derivative
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
J31IL9Z2EE
CAS number
60607-34-3
InChI Key
BAINIUMDFURPJM-UHFFFAOYSA-N
InChI
InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
IUPAC Name
1-{3-[4-(diphenylmethyl)piperazin-1-yl]propyl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1

References

General References
  1. AIFA Product Information: Tinset (oxatomide) for oral and topical use [Link]
Human Metabolome Database
HMDB0240225
KEGG Drug
D01773
PubChem Compound
4615
PubChem Substance
347829033
ChemSpider
4454
BindingDB
76863
RxNav
54236
ChEBI
31943
ChEMBL
CHEMBL13828
ZINC
ZINC000019632896
PharmGKB
PA163522137
Wikipedia
Oxatomide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentDuchenne Muscular Dystrophy (DMD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
GelTopical5 %
Solution / dropsOral0.25 %
Solution / dropsOral25 MG/ML
SuspensionOral25 mg/ml
TabletOral30 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0393 mg/mLALOGPS
logP4.71ALOGPS
logP4.62Chemaxon
logS-4ALOGPS
pKa (Strongest Acidic)12.92Chemaxon
pKa (Strongest Basic)8.01Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area38.82 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity130.94 m3·mol-1Chemaxon
Polarizability48.79 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0000900000-84097f466ddfe2917175
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a6r-1002900000-96951933e0b5d1584ca2
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a59-0009800000-980f59ed3c95834dd143
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-003r-0409700000-b39266881c3ac80d372f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-05qc-4419100000-437c10106d065b610e50
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001m-4926100000-b7d424c751f8d20a8d7c
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-226.8030499
predicted
DarkChem Lite v0.1.0
[M-H]-226.4143499
predicted
DarkChem Lite v0.1.0
[M-H]-194.38414
predicted
DeepCCS 1.0 (2019)
[M+H]+226.0054499
predicted
DarkChem Lite v0.1.0
[M+H]+226.4351499
predicted
DarkChem Lite v0.1.0
[M+H]+196.74214
predicted
DeepCCS 1.0 (2019)
[M+Na]+226.3233499
predicted
DarkChem Lite v0.1.0
[M+Na]+225.8700499
predicted
DarkChem Lite v0.1.0
[M+Na]+203.57559
predicted
DeepCCS 1.0 (2019)

Drug created at October 21, 2016 00:57 / Updated at June 12, 2021 10:54